The effect of empagliflozin on p wave peak time and other p wave parameters in patients with diabetes mellitus
Source : https://onlinelibrary.wiley.com/doi/10.1111/pace.14463
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between...
Conclusion: We found shortening of PWPT, PWdis, and PWD as reflections of improvements in LA volume and LV diastolic function on ECG after empagliflozin treatment.
-
Heart Failure Connect4yrKey Points • Source: Pacing and Clinical Electrophysiology • Conclusions/Relevance: “We found shortening of PWPT, PWdis, and PWD as reflections of improvements in LA volume and LV diastolic function on ECG after empagliflozin Show More
NLRP3 inflammasome as a novel therapeutic target for heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35191381/
Heart failure (HF) is a leading cause of mortality worldwide. The pathogenesis of HF is complex and has not yet been fully elucidated, which has slowed drug development and long-term...
Relevance: In this study, we systematically summarize evidence regarding the relationship among NLRP3 inflammasome, energy metabolism, intestinal microflora metabolites, and inflammation, as well as highlight advantages of NLRP3 inflammasome in treating HF.
Impact of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) On Cardiac Bioenergetic Properties and Cardiorespiratory Fitness: A Special Effect of SGLT2i In Heart Failure? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35191660/
Recent clinical trials have highlighted the profound benefits of Sodium-glucose linked transporter 2 inhibitors (SGLT2i) on cardiovascular mortality and hospitalization for heart failure patients. Modest improvements in glycemic, lipid or...
Conclusion/Relevance: In this review, we discuss the current evidence supporting a shift in myocardial substrate utilization from carbohydrates and fat oxidation towards energy efficient ketone bodies in the failing heart and the role of SGLT2i in this key metabolic adaptation to optimize myocardial fuel energetics. Further insights into the...
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35191586/
For the past two decades, heart failure (HF) has been classified into two phenotypes based on ejection fraction (EF). Inhibitors of the RAAS, neprilysin, , and beta-blockers represent foundational treatments...
Conclusion/Relevance: In the EMPEROR trials, empagliflozin reduced the risk of total HF hospitalizations by approximately 30% in patients with EF ranging from 60-65%. Since patients with an EF >60% represent only 10-15% of all HF patients, we propose that foundational HF treatments should be applied to patients across broad range of EF.
Stopping Empagliflozin Unmasks Heart Failure
About 40% of patients with heart failure (HF) also have type 2 diabetes mellitus (T2DM). 1 Certain sodium-glucose cotransporter-2 (SGLT2) inhibitors have benefited patients with HF. 2 We report a...
Relevance: SGLT2 inhibitors have been shown to have a role in the management of heart failure in patients with type 2 diabetes mellitus, but there is a risk of exacerbation when discontinued.